Quarterly report pursuant to Section 13 or 15(d)

Inventory

v3.21.2
Inventory
6 Months Ended
Jun. 30, 2021
Inventory Disclosure [Abstract]  
Inventory

Note 6: Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. The Company expensed costs related to inventory within the Research and development line in the Consolidated Statements of Operations until it received approval from the FDA to market a product, at which time the Company commenced capitalization of costs relating to that product. Adjustments to inventory are determined at the raw material, sub-assemblies and finished goods levels to reflect obsolescence or impaired balances.

Inventory was as follows:

 

 

 

June 30, 2021

 

 

December 31, 2020

 

Raw materials

 

$

13

 

 

$

130

 

Sub-assemblies

 

 

3,322

 

 

 

2,476

 

Finished goods

 

 

659

 

 

 

928

 

 

 

3,994

 

 

 

3,534

 

Provision for inventory obsolescence

 

 

(436

)

 

 

(556

)

 

$

3,558

 

 

$

2,978